Triple Antihypertensive Composition for Blood Pressure Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing hypertension treatments often result in poor blood pressure control due to poor adherence, complex guidelines, treatment inertia, and limited potency of monotherapy, leading to increased side effects and reduced tolerability.

Innovation Solution

A pharmaceutical composition comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker, administered at doses ranging from 40% to 150% of the lowest hypertension therapeutic dose, to achieve synergistic therapeutic benefits and improved tolerability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If monotherapy with high doses of antihypertensive medications is used, then blood pressure lowering effect is improved, but side effects increase and tolerability is reduced

Engineering Contradiction:

Improveblood pressure controlVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent divides the antihypertensive treatment into three distinct pharmacological components: an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker. Each component is administered at a low dose (40-80% of LHTD), and their combined effect achieves superior blood pressure control compared to high-dose monotherapy, while reducing individual drug exposure and associated side effects.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent creates a composite pharmaceutical composition combining three different antihypertensive agents with complementary mechanisms of action. This multi-component formulation produces a synergistic effect that achieves greater blood pressure reduction than any single agent at high dose, while maintaining better tolerability through lower individual doses.

Inventive Principle:

Principle #40Composite materials

2Reliability

If multiple antihypertensive medications are combined, then blood pressure control is improved, but treatment complexity increases

Engineering Contradiction:

Improveblood pressure controlVSAvoidtreatment regimen

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines three antihypertensive agents into a single pharmaceutical composition or coordinated treatment regimen. By merging these therapies into one standardized combination protocol, the patent simplifies patient adherence and clinical decision-making compared to navigating multiple separate medications and titration steps, while achieving superior blood pressure control.

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If standard therapeutic doses are used, then blood pressure lowering effect is achieved, but tolerability is reduced

Engineering Contradiction:

Improveblood pressure controlVSAvoidlong-term tolerability

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the dosing parameter by administering each component at 40-80% of the lowest hypertension therapeutic dose, rather than at full LHTD. This parameter modification maintains adequate blood pressure control through synergistic interaction while significantly improving long-term tolerability and reducing side effects.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260027093A1Compositions for the treatment of hypertension

Publication Date: 2026.01.29 THE GEORGE INST FOR GLOBAL HEALTH

AI summary

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.